EXHIBIT 23.1
Published on September 26, 2025
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Ocuphire Pharma, Inc. 2020 Equity Incentive Plan of our
report dated March 31, 2025, with respect to the consolidated financial statements of Opus Genetics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
Detroit, Michigan
September 26, 2025